Liang Minmin, Fan Kelong, Zhou Meng, Duan Demin, Zheng Jiyan, Yang Dongling, Feng Jing, Yan Xiyun
Key Laboratory of Protein and Peptide Pharmaceutical, National Laboratory of Biomacromolecules, Chinese Academy of Sciences-University of Tokyo Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China; and.
Key Laboratory of Protein and Peptide Pharmaceutical, National Laboratory of Biomacromolecules, Chinese Academy of Sciences-University of Tokyo Joint Laboratory of Structural Virology and Immunology, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China; and University of Chinese Academy of Sciences, Beijing 100049, China.
Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14900-5. doi: 10.1073/pnas.1407808111. Epub 2014 Sep 29.
An ideal nanocarrier for efficient drug delivery must be able to target specific cells and carry high doses of therapeutic drugs and should also exhibit optimized physicochemical properties and biocompatibility. However, it is a tremendous challenge to engineer all of the above characteristics into a single carrier particle. Here, we show that natural H-ferritin (HFn) nanocages can carry high doses of doxorubicin (Dox) for tumor-specific targeting and killing without any targeting ligand functionalization or property modulation. Dox-loaded HFn (HFn-Dox) specifically bound and subsequently internalized into tumor cells via interaction with overexpressed transferrin receptor 1 and released Dox in the lysosomes. In vivo in the mouse, HFn-Dox exhibited more than 10-fold higher intratumoral drug concentration than free Dox and significantly inhibited tumor growth after a single-dose injection. Importantly, HFn-Dox displayed an excellent safety profile that significantly reduced healthy organ drug exposure and improved the maximum tolerated dose by fourfold compared with free Dox. Moreover, because the HFn nanocarrier has well-defined morphology and does not need any ligand modification or property modulation it can be easily produced with high purity and yield, which are requirements for drugs used in clinical trials. Thus, these unique properties make the HFn nanocage an ideal vehicle for efficient anticancer drug delivery.
Proc Natl Acad Sci U S A. 2014-10-14
Sci China Life Sci. 2022-2
J Nanobiotechnology. 2021-6-13
Chem Commun (Camb). 2025-8-18
Int J Mol Sci. 2025-7-11
Lasers Med Sci. 2025-5-24
Angew Chem Int Ed Engl. 2025-7-21
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025
J Nanobiotechnology. 2025-3-28
Nat Mater. 2013-11
Nat Nanotechnol. 2012-6-17